Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
Healthcare
$18.31 +0.58%
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
52W Low $14.85High $23.00
Volume 0.68M
Average 0.41M
SPTX Sales of Investments
Cash received from selling or redeeming investments.
No reported Sales of Investments figures are available to summarize.
Sales of Investments history
Currency unavailable · from the cash flow
No Sales of Investments data reported for this period type.
Sales of Investments vs competitors
How SPTX compares with its peers on the latest reported figures
SPTX Competitors
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $171.77M USD | -36.5% | — | 858.8% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $168.49M USD | +1.3% | +22.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.63M USD | -44.8% | +51.8% | — |
| LTM Mar 2026 | $151.03M USD | -60.2% | -19.5% | 69.3% | |
| LTM Mar 2026 | $115.03M USD | +39.4% | — | — | |
| LTM Mar 2026 | $63.88M USD | +31.7% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $0 USD | — | +243.9% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -17.6% | +37.0% | 464.1% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Currency unavailable
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.